Skip to main content
Peptyds
Science

Semaglutide vs Retatrutide: The Established Single Agonist Against the Triple

Semaglutide is a single GLP-1 receptor agonist, authorised in the EU as Wegovy for weight management and Ozempic for type 2 diabetes, with roughly 15% mean weight reduction at 68 weeks in the phase 3 STEP 1 trial. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist with no EMA authorisation and roughly 24% at 48 weeks in phase 2. The gap in reported effect is large; so is the gap in how thoroughly each has been tested.

7 min readUpdated 22 Aug 2026Reviewed by Independent EU laboratory (ISO/IEC 17025)
Two lyophilised research peptide vials set apart on a dark laboratory surface, the nearer one fully lit and the further one receding into shadow
Two lyophilised research peptide vials set apart on a dark laboratory surface, the nearer one fully lit and the further one receding into shadow
Jump to section
  1. 01One pathway against three
  2. 02Depth of evidence, not just size of effect
  3. 03EU regulatory status
  4. 04Practical handling is the same
  • Semaglutide activates one receptor. Retatrutide activates three, adding GIP and glucagon.
  • Semaglutide holds EMA authorisations as Wegovy and Ozempic; retatrutide holds none.
  • Reported weight reduction is roughly 15% (semaglutide, phase 3) against roughly 24% (retatrutide, phase 2).
  • Semaglutide has the deepest real-world safety record in the class. Retatrutide's is limited to trial populations.
  • Both are supplied here as research-grade material for laboratory use, not as substitutes for prescribed medicines.

One pathway against three

Semaglutide is a GLP-1 receptor agonist and nothing else. It slows gastric emptying, enhances glucose-dependent insulin secretion and acts on central appetite signalling. That single-pathway design is why its effects and its adverse-event profile are unusually well characterised: there is one mechanism to study.

Retatrutide engages the same GLP-1 receptor, adds GIP, and adds the glucagon receptor. The glucagon arm is the meaningful departure — it raises energy expenditure, where the incretin arms mostly reduce intake. Three simultaneous pathways is the argument for the larger reported effect and also the reason its long-term profile takes longer to establish.

Depth of evidence, not just size of effect

STEP 1 reported roughly 15% mean weight reduction for semaglutide at 68 weeks in a phase 3 population. Retatrutide's phase 2 obesity trial reported roughly 24% at 48 weeks at 12 mg. On effect size alone retatrutide leads clearly.

Effect size is only half the question. Semaglutide has moved through phase 3, gained EMA authorisation, and accumulated years of post-authorisation safety monitoring across very large populations. Retatrutide has a phase 2 dataset. The comparison is between a well-mapped mechanism and a promising one, and no percentage resolves that difference.

EU regulatory status

Semaglutide holds EMA marketing authorisations in the European Union as Wegovy for weight management and Ozempic for type 2 diabetes, each with a published EPAR and an approved label. Retatrutide holds no EMA authorisation for any indication and remains investigational.

Practical handling is the same

Both arrive lyophilised, both require reconstitution with bacteriostatic water, and both need the reconstituted vial kept refrigerated and used within its working window. Neither survives repeated freeze-thaw cycles intact.

Continue reading:How to reconstitute peptidesRetatrutide vs Tirzepatide

Sources

  1. [01]
    European Medicines Agency
    Wegovy EPAR
  2. [02]
    European Medicines Agency
    Ozempic EPAR
  3. [03]
  4. [04]
  5. [05]
  6. [06]
  7. [07]
    European Medicines Agency
    Clinical trials in human medicines
  8. [08]
  9. [09]
  10. [10]
  11. [11]

Questions

Is retatrutide better than semaglutide?

Retatrutide reported a larger mean weight reduction — roughly 24% at 48 weeks in phase 2 against roughly 15% at 68 weeks in phase 3 for semaglutide. But semaglutide is EMA-authorised with years of post-authorisation safety data, and retatrutide is investigational with a phase 2 dataset. Larger reported effect, far less established profile.

Is retatrutide the same as Ozempic?

No. Ozempic is a brand of semaglutide, a single GLP-1 receptor agonist authorised by the EMA for type 2 diabetes. Retatrutide is a different molecule targeting three receptors and holds no authorisation.

Which has more side effects?

Both share the incretin-class gastrointestinal pattern — nausea, diarrhoea, constipation — most pronounced during dose escalation. Semaglutide's profile is characterised across large authorised populations; retatrutide's is currently limited to trial participants, so the honest answer is that one is well mapped and the other is not yet.

Educational content. Not medical advice.

Continue reading

Molecule guides & comparisons

All molecule guides & comparisons articles →
Science
Retatrutide vs Tirzepatide: Triple Agonist Against Dual, and What the Evidence Supports

The two are usually compared on one number — how much weight came off. That number favours retatrutide, and it is also the least useful basis for choosing between them.

8 min read
Science
Semaglutide vs Tirzepatide vs Retatrutide: Mechanisms, Trial Data, and EU Regulatory Status

Three GLP-1 family peptides, three different receptor mechanisms, three different regulatory positions in Europe. Here is what the published trials and the EMA EPARs actually say.

11 min read
Shipping
Buying Peptides Online in Europe: A Quality Checklist

Five concrete checks before checkout: batch CoA from an independent lab, EU fulfilment, temperature handling, transparent storage info, identifiable seller.

7 min read
Next step

Choose the route that matches how you read.

Shop by goalShop all peptidesRead quality protocolView Semaglutide